clinical-trial is the sole category represented across all 1 tracked stories. Definium Therapeutics, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The average consequence score is 6, matching the 6 beat baseline for this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DT120
clinical-trial is the sole category represented across all 1 tracked stories. Definium Therapeutics, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The average consequence score is 6, matching the 6 beat baseline for this window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. DT120 appears in 1 tracked Biotech story from February 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DT120. Shared-story counts are live from our verified record — not editorial picks.
Jefferies analysts have issued a high-conviction outlook on Definium Therapeutics' lead candidate, DT120, assigning a 65-75% probability that the drug will demonstrate best-in-class efficacy in its ongoing Phase III trials. This projection positions the company as a potential disruptor in its therapeutic category, significantly raising market expectations ahead of upcoming data readouts.
